WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 564460
Description: MSD-D is an inhibitor of voltage-gated K(+) (Kv) channels Kv1.5.
MedKoo Cat#: 564460
Chemical Formula: C20H17N3O2S
Exact Mass: 363.1041
Molecular Weight: 363.44
Elemental Analysis: C, 66.10; H, 4.72; N, 11.56; O, 8.80; S, 8.82
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: MSDD; MSD D; MSD-D
IUPAC/Chemical Name: 2-(4-Methoxy-phenyl)-5-methyl-3-oxo-6-p-tolylsulfanyl-2,3-dihydro-pyridazine-4-carbonitrile
InChi Key: YMRVCZZVGOWQDN-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H17N3O2S/c1-13-4-10-17(11-5-13)26-19-14(2)18(12-21)20(24)23(22-19)15-6-8-16(25-3)9-7-15/h4-11H,1-3H3
SMILES Code: N#CC1=C(C)C(SC2=CC=C(C)C=C2)=NN(C3=CC=C(OC)C=C3)C1=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 363.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Strutz-Seebohm N, Gutcher I, Decher N, Steinmeyer K, Lang F, Seebohm G. Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode. Cell Physiol Biochem. 2007;20(6):791-800. PubMed PMID: 17982261.
2: Kiper AK, Rinné S, Rolfes C, Ramírez D, Seebohm G, Netter MF, González W, Decher N. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea? Pflugers Arch. 2015 May;467(5):1081-90. doi: 10.1007/s00424-014-1665-1. Epub 2014 Dec 17. PubMed PMID: 25511502.
3: Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A, Mack AF, Chao CM, Su J, Nitschke R, Alexander D, Friedrich B, Wulff P, Kuhl D, Lang F. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes. 2005 Apr;54(4):1090-9. PubMed PMID: 15793248.